Vbi Vaccines Stock Working Capital
VBI Vaccines fundamentals help investors to digest information that contributes to VBI Vaccines' financial success or failures. It also enables traders to predict the movement of VBI Stock. The fundamental analysis module provides a way to measure VBI Vaccines' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to VBI Vaccines stock.
VBI |
VBI Vaccines Company Working Capital Analysis
VBI Vaccines' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current VBI Vaccines Working Capital | (39.51 M) |
Most of VBI Vaccines' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, VBI Vaccines is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
CompetitionAs per the company's disclosures, VBI Vaccines has a Working Capital of (39.51 Million). This is 109.28% lower than that of the Biotechnology sector and 107.33% lower than that of the Health Care industry. The working capital for all United States stocks is 102.67% higher than that of the company.
VBI Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses VBI Vaccines' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of VBI Vaccines could also be used in its relative valuation, which is a method of valuing VBI Vaccines by comparing valuation metrics of similar companies.VBI Vaccines is currently under evaluation in working capital category among its peers.
VBI Fundamentals
| Return On Equity | -4.2 | |||
| Return On Asset | -0.29 | |||
| Operating Margin | (9.68) % | |||
| Current Valuation | 38.92 M | |||
| Shares Outstanding | 28.68 M | |||
| Shares Owned By Insiders | 6.76 % | |||
| Shares Owned By Institutions | 13.00 % | |||
| Number Of Shares Shorted | 276.87 K | |||
| Price To Earning | (3.79) X | |||
| Price To Book | 1.24 X | |||
| Price To Sales | 0.20 X | |||
| Revenue | 8.68 M | |||
| Gross Profit | (10.19 M) | |||
| EBITDA | (53.32 M) | |||
| Net Income | (92.84 M) | |||
| Cash And Equivalents | 82.41 M | |||
| Cash Per Share | 0.32 X | |||
| Total Debt | 53.04 M | |||
| Debt To Equity | 0.32 % | |||
| Current Ratio | 2.29 X | |||
| Book Value Per Share | (0.22) X | |||
| Cash Flow From Operations | (60.88 M) | |||
| Short Ratio | 1.57 X | |||
| Earnings Per Share | (3.54) X | |||
| Target Price | 5.0 | |||
| Number Of Employees | 131 | |||
| Beta | 2.17 | |||
| Market Capitalization | 1.87 M | |||
| Total Asset | 86.95 M | |||
| Retained Earnings | (582.45 M) | |||
| Working Capital | (39.51 M) | |||
| Current Asset | 7.89 M | |||
| Current Liabilities | 3.03 M | |||
| Net Asset | 86.95 M |
About VBI Vaccines Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze VBI Vaccines's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of VBI Vaccines using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of VBI Vaccines based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Other Consideration for investing in VBI Stock
If you are still planning to invest in VBI Vaccines check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the VBI Vaccines' history and understand the potential risks before investing.
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |